Is bortezomib active in patients with mantle cell lymphoma?

被引：0
|
作者：
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenspital Stadt Wien, Dept Med 1, Ctr Oncol & Haematol, A-1171 Vienna, Austria
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 05期
关键词：
bortezomib; mantle cell lymphoma; response; toxicity;
D O I：
10.1038/ncponc0789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：276 / 277
页数：2
相关论文
共 50 条
  • [1] Is bortezomib active in patients with mantle cell lymphoma?
    Heinz Ludwig
    Nature Clinical Practice Oncology, 2007, 4 : 276 - 277
  • [2] Bortezomib in mantle cell lymphoma
    Sub, K. Stephen
    Goy, Andre
    FUTURE ONCOLOGY, 2008, 4 (02) : 149 - 168
  • [3] Bortezomib treatment for patients with mantle-cell lymphoma
    Tanday, Sanjay
    LANCET ONCOLOGY, 2015, 16 (04): : E162 - E162
  • [4] Bortezomib in the treatment of mantle cell lymphoma
    Robak, Tadeusz
    FUTURE ONCOLOGY, 2015, 11 (20) : 2807 - 2818
  • [5] Bortezomib for the treatment of mantle cell lymphoma
    Kane, Robert C.
    Dagher, Ramzi
    Farrell, Ann
    Ko, Chia-Wen
    Sridhara, Rajeshwari
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5291 - 5294
  • [6] Bortezomib for the treatment of mantle cell lymphoma
    Sun, Danyu
    Smith, Mitchell R.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (11): : 1233 - 1241
  • [7] A phase II study of Bortezomib in patients with mantle cell lymphoma
    Assouline, S
    Belch, A
    Sehn, L
    Kouroukis, CT
    Gascoyne, R
    Meyer, R
    Powers, J
    Eisenhauer, E
    BLOOD, 2003, 102 (11) : 902A - 903A
  • [8] Bortezomib, rituximab, and dexamethason (BORID) is an active salvage regimen for patients with relapsed/refractory mantle cell lymphoma
    Drach, J.
    Kaufmann, H.
    Pichelmayer, O.
    Sagaster, V.
    Holzer, S.
    Zielinski, C.
    Raderer, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 214 - 214
  • [9] Bortezomib for the treatment of mantle cell lymphoma: an update
    Hambley, Bryan
    Caimi, Paolo F.
    William, Basem M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (04) : 196 - 208
  • [10] Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
    Lamm, Wolfgang
    Kaufmann, Hannes
    Raderer, Markus
    Hoffmann, Martha
    Chott, Andreas
    Zielinski, Christoph
    Drach, Johannes
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (07): : 1008 - 1014
12345